Braveheart Bio (NASDAQ:BRVE) Rating Increased to Strong-Buy at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Braveheart Bio (NASDAQ:BRVE) to a strong-buy rating in a report released on Monday morning,Zacks reports.

A number of other analysts have also weighed in on BRVE. Cantor Fitzgerald started coverage on Braveheart Bio in a research note on Monday. They issued an “overweight” rating and a $40.00 target price for the company. The Goldman Sachs Group initiated coverage on shares of Braveheart Bio in a report on Monday. They set a “buy” rating and a $48.00 price objective on the stock. TD Cowen assumed coverage on shares of Braveheart Bio in a research note on Monday. They issued a “buy” rating for the company. Wall Street Zen upgraded shares of Braveheart Bio to a “hold” rating in a research report on Saturday, August 15th. Finally, Stifel Nicolaus assumed coverage on shares of Braveheart Bio in a research note on Monday. They set a “buy” rating and a $45.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating and three have given a Buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $45.25.

Braveheart Bio Stock Performance

Shares of BRVE opened at $25.50 on Monday. Braveheart Bio has a one year low of $24.31 and a one year high of $32.00.

Insider Activity at Braveheart Bio

In related news, major shareholder Bio Fund Iv L.P. Ah acquired 1,100,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average cost of $18.00 per share, with a total value of $19,800,000.00. Following the completion of the purchase, the insider directly owned 10,232,420 shares in the company, valued at approximately $184,183,560. This trade represents a 12.05% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David Charles Lubner acquired 55,555 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was bought at an average price of $18.00 per share, with a total value of $999,990.00. Following the acquisition, the director directly owned 55,555 shares of the company’s stock, valued at $999,990. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have purchased 8,751,942 shares of company stock worth $157,534,956.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.